Tarsier Pharma has expanded its Scientific Advisory Board (SAB).
| TEL AVIV, Israel, March 1, 2022 /PRNewswire/ -- Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for blinding ocular diseases, has expanded its Scientific Advisory Board (SAB). The two new appointments of Prof. Thorne and Prof. Sen will boost support for Tarsier as the Company focuses on phase-3 clinical trials in non-infectious anterior uveitis including uveitic glaucoma, and, on earlier stage development of its pipeline for back-of-the-eye diseases with inflammatory underlying pathologies. They will join existing Scientific Advisory Board members Prof. Cunningham, Prof. Nguyen, and Prof. de Smet.
“This is the dream team we need to help drive Tarsier’s success,” says Dr. Daphne Haim-Langford, CEO and chairperson of Tarsier Pharma. “Prof. Thorne and Prof. Sen are both renowned ocular immunologists, with clinical management experience, alongside research, drug development, and clinical trials expertise, that will serve us well as we go forward in development and commercialization of novel Ophthalmic drugs. They are both key figures in various American and international uveitis forums, which will be essential in helping to increase awareness to the devastating rare condition uveitic glaucoma. We are thankful to add them to our existing exceptional Scientific Advisory Board.” Prof. Jennifer Thorne, M.D., Ph.D., is the Cross Family Professor of Ophthalmology at the Wilmer Eye Institute, where she is also chief of the Division of Ocular Immunology and Uveitis. Prof. Thorne holds a joint appointment as professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health. An internationally recognized and board-certified ophthalmologist, Prof. Thorne is an expert in the evaluation and management of patients with uveitis and other related immune-mediated disorders. “Tarsier Pharma has done incredible work to develop new drugs for patients with ocular inflammatory diseases. There is a substantial unmet need for such drugs, that would be local and potent anti-inflammatory treatments, yet without negative side effects that we know too well from steroidal existing treatments. Unfortunately, uveitis patients usually wait last in line for new therapies, but with Tarsier, they are first, and I am happy to join this important effort”, said Prof. Thorne. Prof. H. Nida Sen, MD, MHS is Professor of Ophthalmology at the George Washington University and Clinical Leader at Janssen Retina R&D, Johnson and Johnson. She has been an investigator at the National Eye Institute (NEI) of the National Institutes of Health (NIH), focusing on mechanism and treatment of uveitis. There she has served as a Lasker Clinical Research Scholar, an NIH Distinguished Scholar, and the Head of Uveitis Clinic and Clinical and Translational Ocular Immunology Section. As a prominent investigator in the field of uveitis and ocular immunology Prof. Sen led many clinical trials and natural history studies throughout her career. She is a board-certified ophthalmologist recognized worldwide as an expert in the field of uveitis and ocular immunology. “Indeed, we know from our everyday experience in the clinic, how much such novel therapies for uveitis are desperately needed, for the patients who seek treatments without significant side effects, and for the healthcare providers who currently have limited tools. I was excited with Tarsier’s story and development, years ago when Tarsier’s CEO first approached me at a uveitis meeting. I am very excited to become now officially part of the journey”, said Prof. Sen. Tarsier’s existing SAB members are:
About Tarsier Pharma Tarsier Pharma is a phase-3 pharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular blinding diseases. TRS is a bio-inspired breakthrough proprietary technology platform, based on a new chemical entity with novel mechanism of action, that demonstrated safety and efficacy in a rare debilitating and blinding indication. Currently Tarsier is running TRS4VISION phase-3 clinical trial in subjects with non-infectious anterior uveitis including uveitic glaucoma. Lead product candidate for uveitic glaucoma Non-infectious uveitis is an autoimmune blinding ocular inflammation, considered the third leading cause of blindness in the developed world. Tarsier’s TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis. Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided due to their side effects of expediting glaucoma and vision loss. Thus, TRS01 has the potential to become the standard of care for uveitic glaucoma. Contact Details:
SOURCE Tarsier Pharma |
View original content to download multimedia:
